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Tumor cell growth inhibition
Mitochondria disruption
Peptide lipid interaction
Lipid model systemsThe peptide KLA (acetyl-(KLAKLAK)2-NH2), which is rather non toxic for eukaryotic cell lines, becomes active
when coupled to the cell penetrating peptide, penetratin (Pen), by a disulﬁde bridge. Remarkably, the conjugate
KLA–Pen is cytotoxic, at low micromolar concentrations, against a panel of seven human tumor cell lines of var-
ious tissue origins, including cells resistant to conventional chemotherapy agents but not to normal human cell
lines. Live microscopy on cells possessing ﬂuorescent labeled mitochondria shows that in tumor cells, KLA–Pen
had a strong impact on mitochondria tubular organization instantly resulting in their aggregation, while the un-
conjugated KLA and pen peptides had no effect. But, mitochondria in various normal cells were not affected by
KLA–Pen. The interaction with membrane models of KLA–Pen, KLA and penetratin were studied using dynamic
light scattering, calorimetry, plasmon resonance, circular dichroism and ATR-FTIR to unveil themode of action of
the conjugate. To understand the selectivity of the conjugate towards tumor cell lines and its action onmitochon-
dria, lipid model systems composed of zwitterionic lipids were used as mimics of normal cell membranes and
anionic lipids as mimics of tumor cell and mitochondria membrane. A very distinct mode of interaction with
the two model systems was observed. KLA–Pen may exert its deleterious and selective action on cancer cells
by the formation of pores with an oblique membrane orientation and establishment of important hydrophobic
interactions. These results suggest that KLA–Pen could be a lead compound for the design of cancer therapeutics.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Since their discovery about 25 years ago, the amount of publications
on cell penetrating peptides (CPPs) has burst. These small peptideswith
their broad cell penetrating ability and lack of toxicity have been used to
deliver a large variety of cargos into cells, ranging from small peptides
and proteins to nucleic acids and nanoparticles [1]. One of the ﬁrst dis-
covered CPPs is penetratin, which corresponds to the third helix of the
Antennapedia homeoprotein, [2] has been the object of numerous stud-
ies both in terms of applications and studies regarding its mechanism of
action [to cite a few examples] [3]. Yet, one of the unsolved issues in the
area of CPPs, that hampers its application in therapeutics, relates to the
lack of selectivity in the targeted tissues, cells or intracellular compart-
ments. Herein, we have coupled penetratin to a proapoptotic peptide
named KLA (acetyl-(KLAKLAK)2-NH2). KLA an amphipathic peptidewas ﬁrst reported as antimicrobial against several bacterial strains
while being non-toxic to eukaryotic cells [4]. The prokaryotic cytoplas-
mic membrane and eukaryotic mitochondrial membranes share com-
mon properties such as the large transmembrane potential and high
content of anionic phospholipids. Based on these facts, KLA peptide,
once in the cell, was then demonstrated to inﬂuence mitochondrial
membrane integrity and to trigger the apoptotic program cell death
[5]. In the oncology research ﬁeld, mitochondria are related to both can-
cer cell expansion and chemotherapy-induced apoptosis. In the recent
years, there is an increasing interest in designing new compounds
targeting mitochondria and multiple review articles in this area have
been published [6].
The coupling of KLA to a tumor blood vessel homing motif showed
anticancer activity in mice [7]. KLA pro-apoptotic properties both
in vivo and in vitro were later re-conﬁrmed with a KLA–CPP conjugate,
i.e.KLA-Arg7 (Arg7 being apolyarginine composed of 7 arginine residues)
[8]. The potential use of this conjugate as an antitumor agent when con-
jugated with the appropriate systemic delivery system and targeting
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cells were killed by apoptosis by antibody-targeted delivery of KLA pep-
tide [9]. More recently, a mixture of the amidated CPP named MPG with
KLA, as well as the conjugation of KLA to a cancer-cell binding peptide
(LTVSPWY) selected from peptide libraries or to a gastrin-releasing pep-
tide (GNHWAVGHLM) were identiﬁed as apoptosis inducers in human
breast adenocarcinoma cells [10].
Herein, KLA and penetratinwere linked through a disulﬁde bond be-
tween two additional Cys residues placed in KLA N-terminus and
penetratin N-terminus. Once inside the cell, the reducing intracellular
milieu should allow the release of KLA as an often employed strategy
[11]. We have investigated the cytotoxic properties of both the conju-
gate KLA–Pen and the isolated peptides KLA and penetratin.We showed
that the conjugate is cytotoxic against a panel of seven human tumor
cell lines of various tissue origins, including cells resistant to some con-
ventional chemotherapy agents. The peptides alone were non toxic. No
toxicity was detected in any of the three non-cancer human cell lines
tested at the same concentrations. We demonstrated that KLA–Pen
had a strong impact on mitochondria tubular organization instantly
resulting in aggregation, selectively in cancer cells. In an attempt to un-
derstand the selectivity of the conjugate towards tumoral cells, we have
looked into differences between the cellular membrane lipid composi-
tion of non-tumor and tumor cells. The eukaryotic plasma membrane
is mainly composed of zwitterionic lipids (80–90%) and the small
amount of anionic lipids is mainly present (4 fold more) in the inner
leaﬂet. Studies have shown that certain tumor cells possess increased
levels of phosphatidylserine in the outer leaﬂet; they can contain up
to 8 fold more PS in their outer leaﬂet than healthy cells [12]. Addition-
ally, they overexpress certain proteoglycans (anionic in nature) like
syndecans and glypicans [13], which endow tumor cells with an en-
hanced anionic character. These differences could explain differences
in terms of binding of the conjugate to the cell membrane and internal-
ization inside cells by endocytosis or direct translocation through the
plasma membrane. As a consequence, we have focused our study on
the differences in terms of the lipid composition between the two
types of cells. Nevertheless, it must be stressed that the differences in
terms of the proteoglycan composition and other proteins could also
be implicated in the selectivity of the conjugate for tumor cells, notably
towards the use of distinct endocytotic pathways. Herein lipid model
systems composed of pure zwitterionic lipids were used as mimics
of non-cancer cell membranes and pure anionic lipids as mimics of
tumor cells. It is certain that these lipid membrane composition are far
from those of cells, herein we use these as general and simple models
in order to get clear cut responses regarding the role of electrostatics
in peptide interaction with tumor cells. Additionally, in view of the
high content of anionic lipids in mitochondria (~30% anionic lipids
like cardiolipin and phosphatidylinositol) the anionic lipid model is
also representative of mitochondrial membranes. Results obtained
with DLS, calorimetry, plasmon resonance, CD andATR-FTIR spectrosco-
py show a very distinct mode of interaction of KLA–Pen with the two
lipid model systems with enhanced membrane interaction and pertur-
bation with anionic membranes. A mechanism of action is proposed
based on these data, explaining the selectivity towards tumor cells of
the conjugate and the action of KLA on the mitochondrial membranes.2. Materials and methods
2.1. Materials
Dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidyl-
glycerol (DMPG), distearoyl phosphatidylcholine (DSPC) and distearoyl
phosphatidylglycerol (DSPG) were purchased from Genzyme
(Switzerland) and were used without further puriﬁcation. Egg PC,
dioleoyl phosphatidylcholine (DOPC) and dioleoyl phosphatidylglycerol
(DOPG) were purchased from Avanti Lipids (Alabama, USA). The acetyl-CRQIKIWFQNRRMKWKK-NH2 peptide was purchased from Neo-Peptide
(Cambridge, UK).
2.2. Peptide synthesis
The peptides acetyl-C(Npys)-(KLAKLAK)2-NH2, acetyl-(KLAKLAK)2-
NH2 and acetyl-RQIKIWFQNRRMKWKK-NH2 were synthesized by
solid phase using the Boc strategy with DCC/HOBt activation (except
for Boc-Cys(NPys)-OH which was activated with DCC only).
The KLA–Pen disulﬁde conjugate was synthesized by dissolving
acetyl-CRQIKIWFQNRRMKWKK-NH2 with 1.2 eq of acetyl-C(Npys)-
(KLAKLAK)2-NH2 in a minimum volume of sodium acetate buffer (50
mM) pH 4.5. The reactionmixture was left overnight at room tempera-
ture and the conjugate was puriﬁed by RP-HPLC on a semi-preparative
C8 column using a linear acetonitrile (0.1% TFA) gradient in an aqueous
solution (0.1% TFA) and characterized by MALDI-TOF MS.
2.3. Human cell lines
The non-small cell lung cancer cell line (A549) and the neuroblastoma
cell line (SK-N-SH) were maintained in RPMI-1640 medium (PAA). For
the resistant EpoB40 and EpoB480 cells (kindly given by SB Horwitz),
which derived from A549 cells, 40 nM and 120 nM Epothilone B was
added, respectively. The colon cancer cell line (SW480), the glioblas-
toma cell line (U251), the embryonic kidney cells (HEK-293 t) and
the keratinocytes (HaCaT) were maintained in DMEM medium
(PAA). The other glioblastoma cell line (U87) was maintained in
MEM medium (PAA). All these culture media were supplemented
with 10% Fetal Calf Serum (FCS), 2 mM L-glutamine and 1% penicillin/
streptomycin (Invitrogen). HEK-293 t also received 1% non-essential
amino acids. The umbilical vein endothelial cells (HUVECs) were grown
in standard culture RPMI 1640 containing 20% heat-inactivated FCS, 2
mM glutamine, 1% penicillin/streptomycin, 50 IU/mL sodium heparin
(Sanoﬁ–Synthelabo), and 50 Ag/mL endothelial cell growth supplement
(BD Biosciences). Cell lines were routinely maintained in culture at 37
°C and 5% CO2 and regularly screened to ensure the absence of mycoplas-
ma contamination (MycoAlert, Lonza).
2.4. Cytotoxicity assay
Growth inhibition was measured using the 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay.
This colorimetric assay allows the monitoring of cell survival in vitro.
For all cell lines, the number of cells seeded (7500 per well for HEK,
U87, U251, A549, EpoB40 and Epo480 cells; 15,000 perwell for HUVECs,
HaCaT, SW480 and SK-N-SH cells) in 96-well plates was ﬁrst optimized
to ensure sustained exponential growth for 4 to 6 days. Cellswere treat-
ed 24 h after seedingwith Pen, KLA, KLA–Pen conjugate, or an extempo-
raneouslymixture of the two peptides for 2, 6 and 24 h. After incubation
with peptides, metabolic activity was detected by addition of MTT
followed by spectrophotometric analysis (550 nm). Cell proliferation
was determined and expressed as a percentage of control (vehicle-
treated) cells. The cytotoxicity assay was also used to determine the
effects of a 24 h treatment followed by a 24 h wash-out period
(i.e. drug-free medium) on cell viability.
2.5. Live ﬂuorescent microscopy of the mitochondrial network
Fluorescence labeling of mitochondria was performed by transfecting
SK-N-SH, U251 and A549 cells with the mitochondrion-targeted DsRed
(mtDsRed) plasmid (ClonTech). Transfections were achieved using
Lipofectamine 2000 (Invitrogen) according to the protocol supplied by
the manufacturer. Stable transfectants were obtained after geneticin
selection (800 μg/mL) for three weeks. A good ﬂuorescence quality was
ensured by cell sorting (FACScan, Becton Dickinson). In SW480, U87,
HUVEC, HEK, and HaCaT cells, ﬂuorescent mitochondria were obtained
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Probes) at 37 °C for 20min. Living cells were then examined using a Leica
DM-IRBE microscope coupled to a digital camera driven by MetaMorph
software (Princeton Instruments).
2.6. Preparation of MLVs, LUVs and SUVs
Lipidﬁlmsweremade bydissolving the appropriate amounts of lipid
in chloroform andmethanol, 2/1 (v/v), followed by solvent evaporation
under nitrogen to deposit the lipid as a ﬁlm on the wall of a test tube.
Final traces of solvent were removed in a vacuum chamber attached
to a liquid nitrogen trap for 3–4 h. Films were hydrated with 10 mM
Tris, 0.1 M NaCl, 2 mM EDTA, pH 7.6 (Tris buffer) (for differential scan-
ning calorimetry DSC, isothermal titration calorimetry ITC, plasmon-
waveguide resonance PWR experiments) or with 10 mM phosphate
buffer, pH 7.6 (for CD, Turbidity and DLS experiments) and vortexed ex-
tensively above the melting temperature (Tm) to obtain multilamellar
vesicles (MLVs). To form large unilamellar vesicles (LUVs), the MLVs
were subjected to ﬁve freeze/thawing cycles. For low concentration of
lipids (~1 mg/mL), the homogeneous lipid suspension was passed 19
times through a mini-extruder (Avanti Alabaster, AL) equipped with
two stacked 100 nm polycarbonate membranes at a temperature
above the phase transition temperature of the lipid. For higher concen-
trations of lipids (~10 mg/mL), the homogeneous lipid suspension was
passed 10 times through a nitrogen pressure driven extruder (LIPEX,
Northern Lipids Inc., BC) equipped with a 100 nm polycarbonate mem-
brane above Tm. Small unilamellar vesicles (SUVs) were obtained by
MLV soniﬁcation using a titanium rod soniﬁer in an ice-water bath to
avoid lipid thermal degradation. Titanium traces were removed by
centrifugation (6000 rpm, 2 min). In all experiments performed the
peptides were added to the lipid model systems after their formation.
2.7. Measurements of liposome turbidity
Changes in aggregation state of vesicles were monitored by absor-
bance measurements at 436 nm. Aliquots of peptide stock solutions
were added to 250 μL suspensions of LUV (lipid concentration, 1250
μM) in 10mM sodium phosphate buffer. The absorbancewasmeasured
using a Jobin-Yvon CD6-SPEX before and after addition of peptide. The
measurements were carried out at 25 and 65 °C.
2.8. Dynamic light scattering
The size distribution of liposomes following peptide addition was
monitored by DLS for both DSPC and DSPG at 25 and 60 °C and for a
peptide/lipid (P/L) ratio of 1/100. Due to peptide precipitation that
occurred at higher peptide concentrations higher P/L ratiowas notmea-
sured. Measurements were performed on a Malvern ZetaSizer Nano ZS
instrument with a detection angle at 173°. Mean hydrodynamic diame-
ters were determined by ﬁtting the normalized time auto-correlation
function of the electric ﬁeld of the scattered light with the cumulant
method and applying the Stokes–Einstein equation.
2.9. Calcein leakage
Calcein-containing LUVsweremade using the same protocol used to
make regular LUVs, except for the hydration step that was performed in
presence of 70 mM calcein. Free calcein was separated from the calcein-
containing LUVs using size exclusion column chromatography (Sephadex
G-75)with Tris as elution buffer. The concentration of lipidswas estimat-
ed using the Rouser protocol [14]. For the assay, the lipid concentration
was set at 1 μM and peptide concentration was allowed to vary to allow
P/L ratios of 1/100, 1/50 and 1/25. All measurements were performed
with a Perkin Elmer LS55 spectrometer (Buckinghamshire, UK). Data
were collected every one second at room temperature using a λexc at485 nm and λem at 515 nm with an emission and excitation slit of
2.5 nm in a 2 mL cuvette.
The ﬂuorescence from calcein at 70 mM concentration was low due
to self-quenching, but increased considerably upon dilution. The ﬂuo-
rescence intensity at the equilibrium was measured after 2.5 h. At the
end of the assay, complete leakage of LUVs was provoked by adding
100 μL of 10%TritonX-100whichdissolved the lipidmembranewithout
interfering with the ﬂuorescence signal. The percentage of calcein
release was calculated according to the following equation:
%Calcein leakage ¼ Ft–Foð Þ= Ff–Foð Þ  100 ð1Þ
where the percent of calcein leakage is the fraction of dye released
(normalizedmembrane leakage), Ft is themeasuredﬂuorescence inten-
sity at time t, and Fo and Ff are respectively the ﬂuorescence intensities
at times t = 0, and after ﬁnal addition of Triton X-100, respectively. A
dilution correction was applied on the ﬂuorescence intensity after
injection of the Triton X-100. Each experiment was repeated three
times.
2.10. Isothermal titration calorimetry (ITC)
ITC experiments were performed on a TA Instrument nano ITC calo-
rimeter. To avoid air bubbles, peptide and LUV solutions were degassed
under vacuum before use. Titrations were performed by injecting ali-
quots of LUVs (10 mg/mL of lipid were used) into the calorimeter cell
containing the peptide solution (peptide concentration 0.1 mM), with
5min waiting between injections (20–50 injections of 5 μL). The exper-
iments were performed at 25 or 60 °C. Data analysis was performed
using the program NanoAnalyze provided by TA Instruments.
2.11. Differential scanning calorimetry (DSC)
Data was acquired on a high-sensitivity differential scanning
calorimeter (Calorimetry Sciences Corporation). A scan rate of 1 °C/min
was used and there was a delay of 10 min between sequential scans in
a series that allows for thermal equilibration. Data analysis was per-
formed with the ﬁtting program CPCALC provided by CSC and plotted
with Igor. The total lipid concentrations used were 1 mg/mL, considering
full hydration of the phospholipid mixtures. At peptide concentrations
corresponding to those at the higher peptide/lipid molar ratios studied
(P/L 1:10), peptides exhibited no thermal events over the temperature
range of 0–100 °C. A minimum of at least three to four heating and
cooling scans were performed for each analysis depending whether or
not the spectra were reproducible.
2.12. Plasmon waveguide resonance (PWR) spectroscopy
PWR spectra are produced by resonance excitation of conduction
electron oscillations (plasmons) by light from a polarized CW laser
(He–Ne; wavelength of 632.8 and 543.5 nm) incident on the back sur-
face of a thin metal ﬁlm (Ag) deposited on a glass prism and coated
with a layer of SiO2 (see ref. [15] for additional information). Experi-
ments were performed on a beta PWR instrument from Proterion
Corp. (Piscataway, NJ) that had a spectral resolution of 1 mdeg. The
method used to prepare the lipid bilayers has been previously described
[15]. The molecules (such as lipids and peptides) deposited onto the
surface plasmon resonator change the resonance characteristics of the
plasmon formation and can thereby be detected and characterized.
PWR resonances can be obtained with light whose electric vector is ei-
ther parallel (s-polarization) or perpendicular (p-polarization) to the
plane of the resonator surface. For oriented molecules, such as the
lipid bilayers information both about mass changes (such as in SPR)
but also changes in the anisotropy (not obtained with SPR) of the
system can be obtained. Data ﬁtting (GraphPad Prism) through a hyper-
bolic saturation curve provides the dissociation constants. Graphical
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formed to determine the contributions of mass and structural changes
for each spectrum [16].
2.13. Circular dichroism (CD) spectroscopy
CD spectra of the peptides were recorded with a Jobin-Yvon CD6-
SPEX dichrograph linked to a PC microprocessor. The instrument out-
puts were calibrated with D(+)-10-camphorsulfonic acid. The spectra
were scanned at 25 °C and 60 °C in a quartz optical cell with a 1 mm
path length. Spectra were recorded between 185 and 260 nm with
0.5 nm step. Eight scans were accumulated and averaged after buffer
(or LUV) spectra subtraction and baseline correction. The peptide con-
centration was varied from 20 to 120 μM in 10 mM phosphate buffer
(pH 7.6) and in presence of DSPC and DSPG LUVs (1250 μM and P/L
ratios from 1/100 to 1/10). CD measurements are reported as Δε
(M−1 cm−1). No detailed analysis on CD spectra components was
performed since deconvolution methods are based on protein structur-
al information and are not straightforwardly adapted to small peptides.
2.14. ATR-FTIR spectroscopy
ATR-FTIR spectrawere recordedwith aNicolet 6700 FT-IR spectrom-
eter (Nicolet Instrument, Madison,WI) equipped with a liquid nitrogen
190 cooled mercury–cadmium–telluride detector on a Germanium
crystal thermostated at 30 °C. ATR spectroscopy is sensitive to orienta-
tion and therefore spectra were recorded with a parallel (p) or perpen-
dicular (s) polarization of the incident light with respect of the ATR
plate. [17] 800 scans were co-added at a resolution of 8 cm−1. Lipid
bilayers were formed by the fusion of SUVs onto the ATR germanium
crystal. Brieﬂy, 20 μL of 1.5 mg/mL SUV solution was deposited on the
crystal containing the Teﬂon cell. After 10–15 min, the non-adsorbed
lipids were rinsed several times with buffer, following addition of
20 μL of deuterated buffer (10 mM Tris–HCl, pH 7.6) before the polar-
ized s and p ATR-FTIR spectra were recorded. Once the bilayer was
formed, the peptides were added to allow a ﬁnal concentration in the
cell of 1 mM. Spectra were recorded over time for both p and s polariza-
tions after rinsing the cell with buffer to remove unbound peptide.
The amide I frequencies were attributed as follows: 1615–1625 cm−1
and 1685–1695 cm−1 antiparallel beta sheet, 1630–1635 cm−1 parallel
beta sheet, 1640–1650 cm−1 random coil, 1650–1662 cm−1 alpha
helix, and 1662–1680 cm−1 beta turn.
3. Results and discussion
3.1. Selective KLA–Pen conjugate cytotoxicity in human cancer cells
To examine the cytotoxic properties of the KLA–Pen conjugate, a
range of human cell lines was used. It consists of seven cancer cell
lines originating from non-small cell lung carcinoma (A549, Epo40,
Epo480), neuroblastoma (SK-N-SH), glioblastoma (U87, U251), and
colon carcinoma (SW480); as well as three non-cancer cell models in-
cluding an embryonic kidney cell line (HEK293), a keratinocyte cell
line (HaCaT) and vascular endothelial primary cells (HUVEC). As
shown in Fig. 1A and B, KLA peptide alone (10 μM)did not exert any sig-
niﬁcant cytotoxic effects against all tested cell lines (p N 0.05). When
conjugated to the cell-penetrating peptide penetratin, KLA–Pen exhibits
signiﬁcant in vitro anticancer activity. The seven different cancer cell
lines were sensitive to the conjugate KLA–Pen (10 μM), which de-
creased cell survival from 40% in U251 cells to almost 70% in A549
cells after a 6 h-treatment (p b 0.01; Fig. 1A). In addition, the two glio-
blastoma cell lines U87 andU251 displayed different levels of sensitivity
(Fig. 1A), supporting the fact that KLA–Pen efﬁcacy does not depend on
the tissue of origin. Interestingly, KLA–Penwas even efﬁcient in decreas-
ing cell survival in lung cancer Epo40 and Epo480 cells (Fig. 1A), which
are highly resistant to conventional chemotherapy, i.e. microtubule-targeted agents (epothilone B or paclitaxel) and cisplatin (personal
data) [18].
Efﬁcacy of the conjugate was time-dependent, since survival of the
same cell line A549 was inhibited by 54 ± 5% and 69 ± 4% after a 2 h
(data not shown) and 6 h-treatment (Fig. 1A) respectively, and reached
84 ± 5% of inhibition after a 24 h-treatment (Fig. 1B). As shown in
Fig. 1C, cancer cells cannot recover from this challenge, since a 24 h-
incubation with KLA–Pen followed by a 24 h drug free period did not
change efﬁcacy of the conjugate. Of note is that it is necessary to conju-
gate KLA to penetratin since the respective effects cannot be met with
the mixture of these peptides, even after a 24 h-incubation with cells
(p N 0.05, Fig. 1B).
Lastly, these cytotoxicity assays revealed a selectivity of the conju-
gate for cancer cells, since none of the three non-cancer cell types tested
was affected by KLA–Pen treatment (10 μM), whatever duration treat-
ment was (p N 0.05; Fig. 1A and B).
3.2. KLA–Pen conjugate potently triggers mitochondrial network disruption
in cancer cells
To further investigate the anticancer activity of KLA–Pen, we gener-
ated various cellularmodels stably expressingmt-DsRed or stainedwith
MitoTracker, and the mitochondrial network was analyzed by live ﬂuo-
rescence microscopy. As expected, in vehicle-treated lung cancer A549
cells, mitochondria form elongated tubular and branched ﬁlaments
(Fig. 2, control). Mitochondrial organization remained unchanged in
A549 cells treated with KLA or penetratin alone (10 μM), for 10 min
and 1 h (Fig. 2, left and right panels respectively) aswell as for 6 h (Sup-
plemental Fig. 1). In contrast, 10 μM of KLA–Pen conjugate highly
disrupted the mitochondrial network organization. The entire A549
cell population displayed clusters ofmitochondria after short time treat-
ments (Fig. 2). We then conﬁrmed the early impact of KLA–Pen on the
mitochondrial architecture in other cancer cell types, since the network
also changes from tubular to spherical in glioblastoma U87, neuroblas-
toma SK-N-SH and colon carcinoma SW480 cells (Fig. 3A and data not
shown). Thus, while KLA and penetratin peptides alone are ineffective,
their conjugation potently affects the mitochondrial organization.
Mitochondria form a highly dynamic network that undergoes constant
fusion and ﬁssion events, leading to changes in their overall morpholo-
gy. These dynamics are essential for maintaining proper physiological
functions and survival of cells [19]. Whereas most studies have focused
on proteins involved in mitochondrial dynamics, growing pieces of evi-
dence show that changes in membrane lipids also actively play roles in
apoptosis induction bymodulating themitochondrialﬁssion/fusion bal-
ance [20]. In that context, our data suggest a direct link between the cy-
totoxicity observed with the KLA–Pen conjugate and the organelle's
excessive fusion. Moreover, in agreement with the cytotoxicity assays,
our results show that KLA–Pen selectively acts on cancer cells, since
the mitochondrial architecture was not altered in non-cancer HUVEC
and HaCaT cells (Fig. 3B). One of the key differences betweenmalignant
and healthy mitochondria may be the high mitochondrial membrane
potential (Δψm) [21]. Even slight gains in Δψm have been proposed
to confer to cationic agents a greater targeting of mitochondrial mem-
branes and, consequently, better membrane permeabilization and cell
death induction in cancer cells [22]. To further provide insight into the
interaction of KLA with mitochondrial membrane lipids, a biophysical
approach has been chosen (3.3 below).
3.3. Mode of interaction of KLA and KLA–Pen peptides with lipids
To mimic both the eukaryotic cell and the mitochondrial membrane
lipid, model systems composed of zwitterionic phosphatidylcholine
(PC) and anionic phosphatidylglycerol (PG)were employed, respective-
ly. One should note that while the outer leaﬂet of a healthy eukaryotic
cell is mainly composed of PC, in the case of cancer cells they become
more anionic. As for the mitochondrial membranes, anionic lipids
Fig. 1. Selective cytotoxic properties of Pen–KLA in cancer cells versus non-cancer cells. Growth inhibition assay performed on a panel of 10 human cell lines using MTT after (A) 6 h in-
cubation or (B) 24 h incubation with vehicle (Ctrl), 10 μM penetratin (Pen), 10 μM KLA, 10 μM of the conjugate (KLA–Pen) or a mixture of 10 μMKLA and 10 μM penetratin (KLA & Pen).
(C) Same experiments were performed after a 24 h treatment followed a 24 h wash-out period. Seven cancer cell lines were ﬁrst used, including non-small cell lung carcinoma sensitive
(A549) or highly resistant to conventional chemotherapy agents (EpoB40 and EpoB480), neuroblastoma (SK-N-SH), glioblastoma (U87, U251), and colon carcinoma (SW480) cells. Then,
three non-cancer cell models including an embryonic kidney cell line (HEK293), a keratinocyte cell line (HaCaT) and vascular endothelial primary cells (HUVEC) were used. Statistical
analysis was performed using Student's t test (*p b 0.05; **p b 0.01).
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models and do not fairly reﬂect the lipid composition of the cellular
membrane, they can provide some ﬁrst clues about the mechanism of
action and selectivity of these peptides.
3.3.1. Peptide effect on liposome size, distribution and membrane integrity
The turbidity of samples and the size distribution of the liposomes
following peptide addition provide information about eventual lipo-
some aggregation and precipitation. None of the peptides changed theturbidity of zwitterionic lipids (DSPC) (data not shown). At 25 °C, all
the peptides strongly increased the turbidity of anionic lipids (DSPG),
which increasedwith the P/L ratio. At 65 °C, KLA did not change the tur-
bidity of liposomeswhile penetratin and KLA–Pen increased slightly the
turbidity, however at high P/L ratio (1/10) (Fig. 2 in SI).
DLS experiments were performed with DSPC and DSPG from 25 to
65 °C (every 5 °C) to scan both below and above the Tm (50–52 °C)
(Fig. 3 in SI). The size and distribution of DSPC alone changed with the
temperature, the objects being large and polydisperse below 50 °C
Fig. 2. Intense anti-mitochondrial effects of Pen–KLA in lung cancer cells. Representative photographs of lung cancer A549 cells stably expressing mtDsRed, incubated for 10 min (left
panel) and 1 h (right panel) with 10 μM penetratin, KLA or KLA–Pen conjugate. Photographs were taken with the 40× objective of a Leica DM-IRBE microscope (scale bars for general
views: 10 μm).Ampliﬁed views showthemitochondrial networkof an individual cell inmore details (scale bars formagniﬁcations: 3 μm). At least three individual experimentswere done.
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DSPC liposomes are slightly larger (~120–140 nm) in the presence of
the KLA–Pen conjugate, KLA or penetratin. This increase in the liposome
size could arise frompeptide interaction, although this does not seem to
be the case as other experiments described below suggest no peptide
interaction with zwitterionic lipids. One other possibility is that TFA
present as counterion in the peptides interacts with the liposomes and
leads to their swelling. At this point we have no other explanation for
this observation. In the case of DSPG, liposomes have a homogeneous
size, of around 100 nm, both below and above the Tm (Fig. 3B in SI).
The addition of penetratin slightly increased the size of liposomes to
about 115 nm below the Tm and the size decreased to about 100
above Tm. The increase in membrane ﬂuidity at higher temperature al-
lows better peptide penetration decreasing liposome size. In the case of
KLA and KLA–Pen, the scenario is different, below Tm the peptides lead
to heterogeneous objects and around Tm values and above both pep-
tides lead to single objects of around 100 nm. This suggests changes in
liposome aggregation and P/L interaction with temperature and will
be further discussed below.Calcein leakage experiments were performed to test the effect of the
peptides on the membrane integrity, as some membrane amphipathic
peptides induce pore formation. The experiments were performed
with DOPC and DOPG, since the lipid must be in the ﬂuid state (which
is the case here at RT) so that there are no inherent membrane defaults
and subsequent calcein leakage. Penetratin does not induce membrane
leakage, while both KLA andKLA–Pen at low concentrations (P/L 1/100)
induce leakage in liposomesmade of DOPG (KLA to a greater extent that
KLA–Pen), but not in liposomes made of DOPC (Fig. 4 in SI). Different
types of pores have been proposed, to explain the action of antimicrobial
and amphipathic peptides, that are composed by peptide alone (laying
perpendicular to themembrane; barrel stavemodel), or amixture of pep-
tide and lipid where the peptide is oriented perpendicular (toroidal
model) or is not oriented at all and works more like a detergent (carpet
model) [23]. The following experiments shed some light on these aspects.
3.3.2. Thermodynamics of the P/L interaction
The afﬁnity of the peptides to lipid model systems was investigated
by ITC using both zwitterionic (DSPC) and anionic (DSPG) lipids with
Fig. 3. Selective anti-mitochondrial effects of Pen–KLA in cancer versus non-cancer cells. (A) Representative photographs of glioblastoma U87 and neuroblastoma SK-N-SH cells stably
expressing mtDsRed, incubated for 1 h with vehicule (control) or 10 μM of KLA–Pen conjugate (scale bars 5 μm). (B) Same experimental conditions with non-cancer HUVECs and
HaCaT cells stainedwithMitoTracker Red (scale bars 10 μm). Photographswere takenwith the 40× objective of a Leica DM-IRBEmicroscope. 2-times ampliﬁed views show themitochon-
drial network of an individual cell in more details. At least three individual experiments were done.
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exchanges observed upon incremental lipid addition to all the peptides
were small and did not follow typical binding isotherms, the interaction
being weak and/or associated with other processes (data not shown).
The nature of KLA binding to DSPG changed with temperature, being
exothermic below Tm and endothermic above, (Table 1, Fig. 4). At 25
°C and at high lipid concentration, precipitation may have occurred, as
indicated by the small positive heats [24]. As far as we know, this is
the ﬁrst example shown in the literature where the sign of enthalpy of
the reaction reversed under the same experimental conditions asidefrom the temperature. Below Tm, the interactions of the amphipathic
KLA are both enthalpy and entropy favorable, reﬂecting good hydrogen
bondingwith the anionic DSPG and favorable hydrophobic interactions.
The hydrophobic face of the peptide could be associatedwith other pep-
tide molecules in a way to protect the hydrophobic face from unfavor-
able solvent interactions (as discussed below, CD results strengthen
this hypothesis). KLA self-association has been previously reported
[25]. Each peptide oligomer could interact with many liposomes
explaining the changes in object size and turbidity induced by KLA in
DSPG at temperatures below Tm. Above the Tm, P/L interactions
Fig. 4. Thermodynamics of P/L interaction. Titration of DSPG into KLA. (A and C) Calorimetric trace obtained at 25 °C and 60 °C, respectively, by titration of DSPG (10.4mM) into a solution
of KLA (100 μM). Each peak corresponds to the injection of 5 μL ofDSPG into the calorimeter cell. (B andD)Heats of reaction (integrated from the calorimetric trace) plotted as a function of
the lipid/peptide ratio. The solid line is the best ﬁt to the experimental data with the parameters presented in Table 1.
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ing is mostly driven by hydrophobic interactions. With the increase in
temperature, the lipid becomes more ﬂuid, which should promote fur-
ther insertion of KLA into the membrane and may disrupt hydrophobic
peptide/peptide interactions that are now occurring between the pep-
tide and the lipid. Such process would explain the decrease in liposome
aggregation and particle size. These changes in KLA/DSPG interactions
as a function of temperature are supported by other data (see below).
Penetratin and KLA–Pen interactions with DSPG lead to exothermic re-
actions both below and above Tm and to KD values in the same range
(Table 1). The stoichiometry (n) that reﬂects the average number of
lipid molecules bound per peptide molecules is very close to the num-
ber of charged residues in the peptide that is exactly 7 in the case of
penetratin and 6 for KLA (Table 1). The experiments were then per-
formed at different temperatures in order to determine the variation
in heat capacity of the reaction (ΔCp) (data in SI, Fig. 5). This parameter
can provide information about the nature of the predominant forces
between the peptide and the lipids. A positive ΔCp is characteristic of
electrostatic interactions that are mostly enthalpy driven while a nega-
tive value indicates a predominance of hydrophobic interactions [26]. A
positive value was found for the interaction of penetratin with DSPG
(3 J/mol) indicating that electrostatic interactions, associated with
favorable enthalpy change, predominate. For KLA and KLA–Pen it was
not possible to determine the value of the ΔCp because at several tem-
peratures (from 40 to 60 °C) the isotherm was complex with bothTable 1
Thermodynamic parameters of peptides binding to DSPG LUVs determined by ITC at 25
and 60 °C.
Peptides Temperature (°C) KD (μM) ΔH (KJ/mol) N
KLA 25 18 −1.5 5
60 8 1.3 5
Penetratin 25 12 −0.5 7
60 21 −0.4 7
KLA–Pen 25 14 −1.9 11
60 16 −1.8 11negative and positive titration peaks. It seems that for these two pep-
tides the variation in temperature greatly affects the nature of the P/L
interactions.
DSCwas performedwith zwitterionic (DSPC andDMPC) and anionic
(DSPG and DMPG) lipids to evaluate the effect of the peptides on the
lipid phase transition. In all cases, addition of KLA has little inﬂuence
on ΔH, but strongly affects Tm, which increases with peptide addition
(Tables 1 and 2 in SI). This increase in Tm suggests that KLA stabilizes
the gel phase state of the membrane. The effect of penetratin on the
zwitterionic lipid phase transition is quite similar to that of KLA. With
the anionic lipids, penetratin leads to a decrease (about 60%) in the en-
thalpy of the transition and an increase in Tm (about 1.5 °C) without
much effect on the cooperativity of the transition (Tables 3 and 4 in
SI). The effect of the KLA–Pen conjugate on the zwitterionic lipid
phase transition is similar to that observed with KLA and penetratin.
Whereaswith anionic lipids, an increase in the Tmwith a large decrease
in the enthalpy of the transition (~60% decrease), were measured as for
penetratin alone (Tables 5 and 6 in SI).
The increase in temperature, cooperativity and enthalpy of the transi-
tion in the case of zwitterionic lipids in the presence of all the peptides
might be related to the changes in the ionic strength of themedium com-
ing from the addition of the cationic peptides and their triﬂuoroacetate
counterions. Changes in pH and ionic composition of the medium have
been shown to alter the lipid phase transition properties [27].3.3.3. Peptide secondary structure and orientation when interacting with
the membrane
In buffer and with zwitterionic lipids (DSPC) the peptides were all
non-structured (random coil) as observed on CD spectra (Fig. 6 in SI).
In the presence of anionic lipids (DSPG), the peptides become struc-
tured in α-helix. The [θ]222/[θ]208 ratio was used to obtain information
on the presence of coiled-coil helices: values greater than 1 indicate
the presence of coiled coils due to peptide self-association values
below 1 are characteristic of non-interacting helices [28]. The capacity
of the peptides to self-associate is affected by the temperature, and so
Fig. 5.KLA interactionwith a DMPGbilayer investigated by PWR. Panels A and B correspond to the PWR spectra of a lipid bilayer alone (solid line) and upon addition of saturating amounts
of KLA (+). The resonance position shifts obtained upon incremental addition of KLA to themembranewith the p- (●) and s-pol (■) are presented in panel C, togetherwith the hyperbolic
binding curve (KD values are presented in Table 6). Panel D corresponds to the kineticmeasurements obtained for the p-pol light upon addition of 0.1 μMof KLA to theDMPG bilayer (rate
constants are provided in Table 3).
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higher than 1 (associated helices) while at 60 °C the ratio is now lower
than 1,meaning that thehelices are isolated. For penetratin and the con-
jugated KLA–Pen, the situation is quite similar to KLA with associated
helices at temperatures below the Tm and isolated helices above it.
Polarized ATR-FTIR spectroscopy provided information on the orien-
tation of the peptide relative to the lipid membrane as well as effects of
the peptide on the lipid organization [29]. The experiments were per-
formed with DMPC and DMPC/DMPG (8/2 mol/mol) so that the lipids
are ﬂuid at room temperature. No pure anionic lipid was used, as in
other experiments because from our own experience membranes can-
not be formed by SUV fusion containing pure PG (the maximum quan-
tity of PG that can be used is 20–30%). In the case of DMPC, for all
peptides investigated, no typical peptide secondary structure bands
were observed (amide I and II bands), even at high concentration of
peptide (1mM). Additionally, no changewas induced in the lipid typical
bands, further suggesting that the peptide did not interact withzwitterionic lipids. But, in the presence of DMPG (20% relative to
DMPC), all the cationic peptides remained attached even after washing
the cell with buffer and incorporated into the membrane with a P/L
around 1/150. The decomposition of the amide I band in single compo-
nent characteristic of each secondary structure (Fig. 7 in SI) allowed the
determination of the peptides secondary structures in the presence of
this lipid (Table 2). The three peptides display quite comparable second-
ary structure with a predominance of random coil (40%) and α-helix
(30%) following by some antiparallel β-sheet (20%) and some β-turn
and/or signal corresponding to TFA (10%), (this counterion absorbs in
the same region as the β-turn, around 1670 cm−1). The orientation of
the α-helix in the peptide was estimated from the dichroic ratio (ob-
tained from the p and s polarized spectra). With a value close to 1 for
penetratin, theα-helical component of the Pen is lying ﬂat on the lipid bi-
layer. In the case of both KLA and KLA–Pen, the dichroic ratio around 1.6–
1.7 suggests a tilted orientation of the helix main axis with an angle
around 55° with the respect to the crystal normal (Table 2). This tilted
Table 2
Secondary structure of the peptides in presence of DMPC/DMPG (8/2 mol/mol) as determined by ATR-FTIR.
Secondary structure composition (%) KLA (P/L ≈ 1/150) Penetratin (P/L ≈ 1/135) KLA–Pen (P/L ≈ 1/155)
Antiparallel β-sheet 18 21 16
Random 43 35 39
α-Helix 34 (RATR ≈ 1.6) 29 (RATR ≈ 1.0) 35 (RATR ≈ 1.7)
β-Turna 5 15 10
a The triﬂuoroacetate (TFA) counterions for the peptides strongly contribute also to this region.
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duced by both KLA andKLA–Penwith the formation of pores in themem-
brane (see above). The preference for this particular peptide orientation
suggested a pore of the type barrel stave or toroidal rather than a mech-
anism by detergent disruption. Regarding peptide effects on lipid organi-
zation, none of the peptides signiﬁcantly affected the Ap/As ratios of the
symmetric stretching of CH2,meaning that overall they did not greatly af-
fect the acyl chain orientation. However, the absolute values of all the
methylene wavenumbers increased for all the peptides (variations
ranged from3 to 7 cm−1). Such increase indicates that the peptides insert
deeply enough in the fatty acid chain region of themembrane andmodify
the lipid organization inducing an increase of disorder.3.3.4. Afﬁnity and kinetics of peptide interaction with lipids and subsequent
lipid reorganization
Plasmon waveguide resonance (PWR) was used to determine the
afﬁnity and kinetics of peptide interaction with planar lipid bilayers
composed of DMPC and DMPG in the ﬂuid phase. The addition of KLA,
penetratin or KLA–Pen to a DMPC lipid bilayer (for concentrations up
to 100 μM of peptide in the cell) did not produce signiﬁcant shifts in
the resonance angle position (data not shown), suggesting that none
of these peptides interacts with this zwitterionic lipid. The results corre-
late well with ITC experiments that also indicate a lack of interaction
with DMPC (data not shown). In the case of DMPG, KLA leads to a de-
crease in the resonance angle position for both polarizations (Fig. 5,
Table 5 in SI), which corresponds to a decrease in mass in the system.
Such mass loss can be due to a partial solubilization of the membrane
and/or pore formation, which correlates well with calcein leakage stud-
ies. The spectral shifts induced by the peptide were anisotropic (with
shifts in the p-polarization being higher than in s-polarization), indicat-
ing that the peptide induces larger changes in mass and structure per-
pendicularly to the membrane. Such results corroborate well with
ATR-FTIR studies suggesting an oblique orientation of the peptide
helix within the bilayer. A graphical analysis was performed to deter-
mine the structural and mass contributions to the spectral change
(Table 4 in SI). A major mass contribution was observed with a value
of 85% for KLA and an apparent dissociation constant for P/L interaction
was determined to be 0.1 μM from the resonance minimum position
changes as a function of peptide concentrations, (Fig. 5, Table 3). Addi-
tionally, the kinetics of the interaction with the bilayer was followed
by measuring the resonance minimum position as a function of time
upon addition of 0.1 μMof KLA to the DMPGmembrane. A rate constant
of 0.032 s−1was determined for this interaction (Table 3). As previously
reported for penetratin, its interaction with DMPG lead to an apparent
KD value of 0.3 μM with and a kinetic constant of 0.090 s−1, which is
slightly faster but in the same magnitude as that observed for KLA
(Table 3) [30]. For KLA–Pen, like KLA the spectral changes wereTable 3
Afﬁnity and kinetics of the interaction of the peptideswith DMPG lipid bilayer determined
by PWR.
Peptides KD (μM) k (s−1)
KLA 0.1 ± 0.003 0.032 ± 0.002
Penetratin 0.3 ± 0.002 0.090 ± 0.004
KLA–Pen 0.1 ± 0.002 0.045 ± 0.005
The constants result from 3 independent experiments.dominated by mass changes, (Table 4 in SI), (in this case decreases in
mass) mainly attributed to lipid reorganization (as explained above).
An apparent KD value of 0.1 μM was observed and a kinetic constant
of 0.045 s−1 (Table 3).4. Conclusions
CPPs have become important tools for the cellular delivery of a wide
range of molecules including pharmaceuticals. The proapoptotic pep-
tide KLA cannot efﬁciently permeate across eukaryotic plasma mem-
branes and consequently exhibits low mammalian cell cytotoxicity.
We chose here to conjugate it to the cell penetrating peptide penetratin
to facilitate cellular uptake. We ﬁrst demonstrated that the conjugated
KLA–Pen peptide has cytotoxic properties against a panel of seven
human cancer cell lines of various tissue origins, including cells resistant
to some conventional chemotherapy agents. Interestingly, KLA–Pen did
not affect, at the same concentration, the different human non-cancer
cell lines or primary cultures, highlighting a selective anti-cancer activ-
ity in vitro for this conjugated peptide. In an attempt to understand
some of the reasons behind KLA–Pen selectivity for tumor cells and
deleterious action on mitochondrial membranes, a biophysical ap-
proach was used with simple lipid membrane models mimicking nor-
mal and tumor eukaryotic cell membranes, as well as mitochondrial
membranes. While differences in terms of the proteoglycan composi-
tion between tumor and non-tumor cell lines have been reported in
the literaturewhichmay affect the endocytic pathway taken by the con-
jugate in the types of cells, herein we have only focused on the differ-
ences in lipid composition of the two cell types. The results show that
KLA–Pen interacts and affects the organization of an anionic lipid mem-
branemodel (representative model of a cancer cell membrane) while it
does not bind to a zwitterionicmembrane (non-cancer cell membrane).
Indeed with anionic lipids the conjugate leads to liposome aggregation
and leakage, has a disordering effect on lipid organization and inserts
in membrane with a tilted orientation relative to the membrane. The
KLA–Pen conjugate may exert its deleterious action on charged mem-
branes by the formation of pores where the conjugate orients obliquely
in the membrane and establishes important hydrophobic interactions.
Such selective interaction with anionic membranes supports the selec-
tivity observed in cancer cells. Membranes of cancer cells have also
been reported to be more ﬂuid than those of “normal” cells, which
may further facilitate peptide penetration and perturbation [31]. Very
preliminary results obtained with propidium iodide showed that KLA–
PEN could increasemore efﬁciently theﬂuorescent probe uptake in can-
cer cells as compared with non-cancer cells (personal data). Neverthe-
less, a complete examination of phosphatidylserine composition and
efﬂux/inﬂux through plasma membrane of cancer and non-cancer
cells will be necessary to clarify the mechanism behind the selective
targeting of KLA–Pen conjugate.
Cancer cell death induction upon chemotherapy drug treatment has
been generally linked to mitochondrial fragmentation into small indi-
vidual organelles [32]. In contrast, the present study suggests that the
KLA–Pen conjugate induces an excessive fusion of mitochondria in can-
cer cells, resulting in huge damages in the mitochondrial architecture
and in the inhibition of their metabolic activity [33]. Once inside the
cell, KLA is rather active towards the mitochondria which, among
other properties, are characterized by the marked anionic character
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physical studies with anionic membranes (i.e. representative of mito-
chondria anionic character) demonstrate the strong impact of this
peptide on the supramolecular organization of lipids with strong lipo-
some aggregation, leakage (formation of pores) and lipid disordering ef-
fects. Interestingly, these processes correlate with both the effects we
observed on mitochondrial network architecture, and the well-known
KLA-mediated release of pro-apoptotic factors from mitochondria that
ultimately results in cell death.
Overall, the biophysical studies performed allowed us to conclude
that, in addition to electrostatic interactions that might be at the origin
of the observed selectivity, interactions of KLA and the conjugate pep-
tidewith lipids is verymuch inﬂuenced by theﬂuidity state of themem-
brane (a process dependent on both membrane composition and
temperature). Such parameters (electrostatics, membrane ﬂuidity and
temperature) seem to also inﬂuence the oligomerization state of the
peptide, which strongly affects the peptide mode of action. Here very
simple lipid model systems were used that are quite far from the real
composition of a cell or mitochondria membrane. Nonetheless these
studies provide us some clues on the mechanism of action of these
peptides. Future studies with models whose composition resembles
more in the cell membrane and mitochondria are considered. The
mitochondria have recently gained in interest since they are now
considered as potential druggable targets for successful rational drug
design and therapy. The key point is that strategies that directly engage
mitochondria could bypass resistance to apoptosis that normally arises
as a consequence of accumulation ofmutations in apoptosis signaling in-
termediates upstream of mitochondria in a variety of cancers [34]. Com-
bining mitochondria-targeted peptides with low doses of conventional
chemotherapy may thus be a powerful strategy to synergistically induce
cancer cell death while reducing acquired resistance and side effects.
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